• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Apogee Therapeutics, Inc. - Common Stock (NQ:APGE)

    134.15 +0.15 (+0.11%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 20, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Apogee Therapeutics, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 Next >
    News headline image
    How Will AbbVie's $10.9 Billion Acquisition of Apogee Impact Its Dividend? ↗
    There's no need to panic. 
    Via The Motley Fool
    News headline image
    My 2 Favorite Dividend Kings to Buy Right Now ↗
    They can help stabilize your portfolio in these otherwise volatile times. 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Halper Sadeh LLC is Investigating Whether NEE, CRBG, RMAX, APGE are Obtaining Fair Deals for their Shareholders
    From Halper Sadeh LLC
    Via GlobeNewswire
    News headline image
    What This Apogee Insider Move Might Mean After a 247% Stock Run ↗
    Henderson's disposition included a 20,000-share open-market sale and a 75,046-share charitable gift. 
    Via The Motley Fool
    Topics Regulatory Compliance
    Apogee Therapeutics (NASDAQ:APGE) Beats Q1 Estimates with Strong Cash Runway and Promising Clinical Progress ↗
    Via Chartmill
    News headline image
    AbbVie Is Already a Dividend King. Here's Why the $10.9 Billion Apogee Deal Could Make It a Dynasty ↗
    AbbVie inherited its status as a Dividend King, but it is building a strong foundation to continue the dividend streak. 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    The Dividend ETF Quietly Outperforming the S&P 500 ↗
    This dividend ETF's focus beyond yield continues to pay off for investors. 
    Via The Motley Fool
    Topics ETFs Stocks
    News headline image
    Shareholder Alert: Ademi LLP investigates whether Apogee Therapeutics is obtaining a Fair Price for Public Shareholders
    From Ademi LLP
    Via GlobeNewswire
    News headline image
    This Pharmaceutical Giant Just Poured $11 Billion on an Acquisition. Time to Buy? ↗
    AbbVie knows how to plan ahead. 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Apogee Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apogee Therapeutics, Inc. - APGE
    From Kahn Swick & Foti, LLC
    Via Business Wire
    News headline image
    Halper Sadeh LLC is Investigating Whether APGE, LPRO, HUN, AVNS are Obtaining Fair Deals for their Shareholders
    From Halper Sadeh LLC
    Via GlobeNewswire
    In today's session, these stocks are experiencing unusual volume. ↗
    Via Chartmill
    News headline image
    Why AbbVie Stock Jumped Today ↗
    An intriguing acquisition could bring exciting new drugs into the medicine maker's development pipeline. 
    Via The Motley Fool
    News headline image
    AbbVie's $10.9 Billion Apogee Deal Will Extend Its Immunology Dominance: Is It Time to Load Up on This Dividend King? ↗
    The company is already renowned by many as a giant in the segment. 
    Via The Motley Fool
    News headline image
    Stock Market Today, June 22: Apogee Therapeutics Soars on AbbVie Cash Buyout Offer ↗
    On June 22, 2026, Apogee Therapeutics shares surged as investors reacted to AbbVie's proposed acquisition terms. 
    Via The Motley Fool
    Topics Stocks
    Top movers analysis one hour before the close of the markets on 2026-06-22: top gainers and losers in today's session. ↗
    Via Chartmill
    News headline image
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Apogee Therapeutics, Inc. (Nasdaq – APGE), Simulations Plus, Inc. (Nasdaq – SLP), Roku, Inc. (Nasdaq – ROKU), TruBridge, Inc. (Nasdaq – TBRG)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    Which stocks are moving on Monday? ↗
    Via Chartmill
    Monday's session: gap up and gap down stocks ↗
    Via Chartmill
    News headline image
    APGE Stock Alert: Halper Sadeh LLC is Investigating Whether Apogee Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders
    From Halper Sadeh LLC
    Via Business Wire
    These stocks that are showing activity before the opening bell on Monday. ↗
    Via Chartmill
    News headline image
    Apogee Therapeutics Maps Phase 3 Push for Zumilokibart, Backed by Blackstone Funding ↗
    Apogee Therapeutics (NASDAQ:APGE) executives outlined plans to advance zumilokibart, the company’s IL-13-targeting antibody, into late-stage development for atopic dermatitis while expanding the... 
    Via MarketBeat
    Topics Initial Public Offering
    News headline image
    Apogee Therapeutics Readies Zumi for Phase 3 With Blackstone Backing ↗
    Apogee Therapeutics (NASDAQ:APGE) executives said the company is preparing to move its lead drug candidate, zumilokibart, into Phase 3 testing later this year after reporting Phase 2b data in atopic... 
    Via MarketBeat
    Topics Initial Public Offering
    News headline image
    Apogee Therapeutics to Participate in Upcoming June Conferences
    From Apogee Therapeutics
    Via GlobeNewswire
    News headline image
    Apogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of Zumilokibart
    From Apogee Therapeutics
    Via GlobeNewswire
    News headline image
    Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitis
    From Apogee Therapeutics
    Via GlobeNewswire
    News headline image
    Apogee Therapeutics to Host Conference Call to Report Part B 16-Week Data from the Phase 2 APEX Trial of Zumilokibart in Patients with Moderate-to-Severe Atopic Dermatitis on May 27, 2026
    Webcast to be held Wednesday, May 27th at 8:00 a.m. ET 
    From Apogee Therapeutics
    Via GlobeNewswire
    News headline image
    Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results
    From Apogee Therapeutics
    Via GlobeNewswire
    News headline image
    Eli Lilly Shares Slip Despite Positive Eczema Trial Results: Why the Market Reacted Coolly
    INDIANAPOLIS – In a move that has left some retail investors scratching their heads, shares of Eli Lilly and Company (NYSE:LLY) have trended lower this week, despite the pharmaceutical giant releasing... 
    Via MarketMinute
    News headline image
    Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $403 Million
    From Apogee Therapeutics
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.